DMK PHARMACEUTICALS Corp financial data

Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2023 - 14 Nov 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 53.3 % -73.8%
Quick Ratio 6.12 % +33.9%
Debt-to-equity -219 % -341%
Return On Assets -264 % -104%
Operating Margin -719 % +62.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.1M shares -93.3%
Common Stock, Shares, Outstanding 10.1M shares -93.3%
Common Stock, Value, Issued 1.01K USD -93.3%
Weighted Average Number of Shares Outstanding, Basic 7.07M shares +230%
Weighted Average Number of Shares Outstanding, Diluted 7.07M shares +230%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 3.53M USD +138%
Research and Development Expense 7.47M USD -43.6%
Operating Income (Loss) -25.3M USD +11.7%
Nonoperating Income (Expense) 4.18M USD +328%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9.01M USD +11.5%
Net Income (Loss) Attributable to Parent -22.2M USD +30.4%
Earnings Per Share, Basic 2 USD/shares +90.2%
Earnings Per Share, Diluted 2 USD/shares +90.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.66M USD +175%
Inventory, Net 663K USD -39.3%
Other Assets, Current 67.2K USD
Assets, Current 7.87M USD -22%
Property, Plant and Equipment, Net 1.08M USD -32.6%
Operating Lease, Right-of-Use Asset 146K USD -70%
Other Assets, Noncurrent 9.67K USD -81.5%
Assets 8.96M USD -26.2%
Accounts Payable, Current 9.97M USD +88.3%
Accrued Liabilities, Current 2.32M USD +73.2%
Liabilities, Current 13.5M USD +51.7%
Liabilities 13.9M USD +52.4%
Retained Earnings (Accumulated Deficit) -323M USD -7.38%
Stockholders' Equity Attributable to Parent -5.29M USD -286%
Liabilities and Equity 8.96M USD -26.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.55M USD +77.8%
Net Cash Provided by (Used in) Financing Activities 2.72M USD
Net Cash Provided by (Used in) Investing Activities 842K USD -45.1%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 10.1M shares -93.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.02M USD
Depreciation 636K USD -56.9%
Operating Lease, Liability, Current 63.2K USD -82.9%
Preferred Stock, Shares Authorized 10M shares
Share-based Payment Arrangement, Expense -249K USD -160%
Interest Expense 29.5K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares